NCT03696303View on ClinicalTrials.gov

Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala

CompletedOBSERVATIONAL
Enrollment

959

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Community-acquired PneumoniaStreptococcus Pneumoniae Infection
Interventions
OTHER

Urinary antigen detection assay

Screening for Ag level in S. pneumoniae urinary antigen detection assay.

Trial Locations (3)

Unknown

Hospital Regional Cuilapa, Cuilapa

01009

Hospital General IGSS, Guatemala City

01011

Hospital Roosevelt, Guatemala City

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT03696303 - Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala | Biotech Hunter | Biotech Hunter